HUMAN TUMOUR-ASSOCIATED MONOCLONAL ANTIBODY Russian patent published in 2013 - IPC C07K16/00 A61K39/395 A61P35/00 C12N15/13 C12N15/63 G01N33/53 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses new human tumour-associated antibody and fragments thereof able to recognize the tumour-associated antigen NY-ESO-1, containing CDR1, CDR2 and CDR3 sequenced in a certain way in a variable region of a heavy chain and a variable region of a light chain as presented in the description, or containing CDR2 and CDR3 differing by one, two or three amino acids from the respective sequences. There are described polynucleotide coding a variable area of a immunoglobulin chain of the antibody, a vector for polynucleotide transfer and/or expression, and a host cell for producing the antibody or binding fragment thereof. There are also described pharmaceutical compositions containing the above antibodies and binding fragments thereof for treating tumours, as well as a kit for diagnosing cancer diseases, such as primary carcinoma, breast cancer and metastases.

EFFECT: antibodies under the invention while being human ones, are more specifically targeted on tumour tissue and cells.

20 cl, 4 dwg, 3 ex